- Home
- GOSS vs ODV Comparison
GOSS vs ODV Comparison
Compare GOSS & ODV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- ODV
- Stock Information
- Founded
- GOSS 2015
- ODV 2005
- Country
- GOSS United States
- ODV Canada
- Employees
- GOSS N/A
- ODV N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- ODV Precious Metals
- Sector
- GOSS Health Care
- ODV Basic Materials
- Exchange
- GOSS Nasdaq
- ODV Nasdaq
- Market Cap
- GOSS 347.8M
- ODV 338.9M
- IPO Year
- GOSS 2019
- ODV N/A
- Fundamental
- Price
- GOSS $2.47
- ODV $2.72
- Analyst Decision
- GOSS Strong Buy
- ODV
- Analyst Count
- GOSS 4
- ODV 0
- Target Price
- GOSS $8.50
- ODV N/A
- AVG Volume (30 Days)
- GOSS 3.1M
- ODV 1.1M
- Earning Date
- GOSS 08-05-2025
- ODV 08-12-2025
- Dividend Yield
- GOSS N/A
- ODV N/A
- EPS Growth
- GOSS N/A
- ODV N/A
- EPS
- GOSS N/A
- ODV N/A
- Revenue
- GOSS $40,237,000.00
- ODV $5,147,156.00
- Revenue This Year
- GOSS N/A
- ODV $381.12
- Revenue Next Year
- GOSS $30.65
- ODV $256.81
- P/E Ratio
- GOSS N/A
- ODV N/A
- Revenue Growth
- GOSS N/A
- ODV N/A
- 52 Week Low
- GOSS $0.66
- ODV $1.16
- 52 Week High
- GOSS $2.65
- ODV $2.91
- Technical
- Relative Strength Index (RSI)
- GOSS 68.08
- ODV 60.30
- Support Level
- GOSS $2.38
- ODV $2.43
- Resistance Level
- GOSS $2.65
- ODV $2.91
- Average True Range (ATR)
- GOSS 0.15
- ODV 0.14
- MACD
- GOSS 0.03
- ODV 0.02
- Stochastic Oscillator
- GOSS 76.67
- ODV 64.08
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About ODV Osisko Development Corp.
Osisko Development Corp is a mineral exploration and development company engaged in the acquisition, exploration, and development of precious metals resource properties in North America. The company is focused on exploring and developing its mining assets, including the Cariboo Gold Project in British Columbia, the San Antonio gold project in Mexico, and the Trixie test mine in the USA. The Company manages its business through the exploration, evaluation, and development activities of its projects.